Sands Capital Life Sciences Pulse Fund II L.P. 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-13 11:17 am Unchanged | 2025-06-30 | 13G | Inhibikase Therapeutics, Inc. IKT | Sands Capital Life Sciences Pulse Fund II L.P. | 10,950,000 14.700% | 0 (Unchanged) | Filing |
| 2024-10-25 5:50 pm Purchase | 2024-10-21 | 13G | Inhibikase Therapeutics, Inc. IKT | Sands Capital Life Sciences Pulse Fund II L.P. | 10,950,000 16.300% | 10,950,000 (New Position) | Filing |